Medical comorbidity in late-life bipolar disorder

Bipolar Disorder in Later Life

Volumn , Issue , 2007, Pages 162-181

  Kales, Helen C ^a,b,c  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b VA ANN ARBOR HEALTHCARE SYSTEM   (United States)

^c DEPARTMENT OF VETERANS AFFAIRS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84859312945     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (95)

1. Abbott, F. S., Kassam, J., Orr, J. M., et al. 1986. The effect of aspirin on valproic acid metabolism. Clin Pharmacol Ther 40:94-100.
2. Ahn, K. H., Lyoo, I. K., Lee, H. K., et al. 2004. White matter hyperintensities in subjects with bipolar disorder. Psychiatry Clin Neurosci 58:516-521.
3. Alexopoulos, G. S., Meyers, B. S., Young, R. C., et al. 1997. "Vascular depression" hypothesis. Arch Gen Psychiatry 54:915-922.
4. Allison, D. B., and Casey, D. E. 2001. Antipsychotic-induced weight gain: a review of the literature. J Clin Psychiatry 62(suppl.):22-31.
5. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, and North American Association for the Study of Obesity. 2004. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 27:596-601.
6. Anthenelli, R. M. 2005. Treating patients with bipolar disorder and COPD or asthma. Curr Psychiatry 4(suppl.):34-42.
7. Aweeka, F., Jayesekara, D., Horton, M., et al. 2000. The pharmacokinetics of ziprasidone in subjects with normal and impaired renal function. Br J Clin Pharmacol 49(suppl. 1):27S-33S.
8. Baptista, T., Teneud, L., Contreras, Q., et al. 1995. Lithium and body weight gain. Pharmacopsychiatry 28:35-44.
9. Benabarre, A., Vieta, E., Martinez-Aran, A., et al. 2005. Neuropsychological disturbances and cerebral blood flow in bipolar disorder. Aust N Z J Psychiatry 39:227-234.
10. Benowitz, N. L. 1984. Effects of cardiac disease on pharmacokinetics: pathophysiologic considerations. In Benet, L. Z., Massoud, N., and Gambertoglio, J. G. (eds.), Pharmacologic basis for drug treatment. New York: Raven Press.
11. Bernus, I., Dickinson, R. G., Hooper, W. D., et al. 1997. Anticonvulsant therapy in aged patients: clinical pharmacokinetic considerations. Drugs Aging 10:278-289.
12. Berrios, G. E., and Bakshi, N. 1991. Manic and depressive symptoms in the elderly: their relationships to treatment outcome, cognition, and motor symptoms. Psychopathology 24:31-38.
13. Beyer, J. L., Kuchibhatla, M., Looney, C., et al. 2003. Social support in elderly patients with bipolar disorder. Bipolar Disord 5:22-27.
14. Beyer J., Kuchibhatla, M., Gersing, K., et al. 2005. Medical comorbidity in a bipolar outpatient clinical population. Neuropsychopharmacology 30:401-404.
15. Blazer, D., Hughes, D. C., and George, L. K. 1992. Age and impaired subjective support: predictors of depressive symptoms at one-year follow-up. J Nerv Ment Dis 180:172-178.
16. Boton, R., Gaviria, M., and Batlle, D. C. 1987. Prevalence, pathogenesis, and treatment of renal dysfunction associated with chronic lithium therapy. Am J Kidney Dis 10:329-345.
17. Brown, S. 2001. Variations in utilization and cost of inpatient psychiatric services among adults in Maryland. Psychiatr Serv 52:841-843.
18. Busch, J. A., Radulovic, L. L., Bockbrader, H. N., et al. 1992. Effect of Maalox TC on singledose pharmacokinetics of gabapentin capsules in healthy subjects. Pharm Res 9(suppl.):315S.
19. Calabrese, J. R., Shelton, M. D., Rapport, D. J., et al. 2002. Bipolar disorders and the effectiveness of novel anticonvulsants. J Clin Psychiatry 63(suppl. 3):5S-9S.
20. Carruthers, S. G. 1994. Adverse effects of alpha 1-adrenergic blocking drugs. Drug Saf 11:12-20.
21. Cassidy, F., Ahearn E., and Carroll, B. J. 1999. Elevated frequency of diabetes mellitus in hospitalized manic-depressive patients. Am J Psychiatry 156:1417-1420.
22. Cassidy, F., and Carroll, B. J. 2002. Vascular risk factors in late onset mania. Psychol Med 32:359-362.
23. Coresh, J., Astor, B. C., Greene, T., et al. 2003. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: third national health and nutrition examination survey. Am J Kidney Dis 41:1-12.
24. Das Gupta, K., and Jefferson, J. W. 1990. The use of lithium in the medically ill. Gen Hosp Psychiatry 12:83-97.
25. Depp, C. A., Lindamer, L. A., Folsom, D. P., et al. 2005. Differences in clinical features and mental health service use in bipolar disorder across the life span. Am J Geriatr Psychiatry 13:290-298.
26. Dewan, N. A., Suresh, D. P., and Blomklans, A. 2003. Selecting safe psychotropics for post-MI patients. Curr Psychiatry 2:14-21.
27. Dhingra, U., and Rabins, P. V. 1991. Mania in the elderly: a five-to-seven year follow-up. J Am Geriatr Soc 39:581-583.
28. Elmslie, J. L., Mann, J. I., Silverstone, J. T., et al. 2001. Determinants of overweight and obesity in patients with bipolar disorder. J Clin Psychiatry 62:486-491.
29. Ereshefsky, L. 1996. Pharmacokinetics and drug interactions: update for new antipsychotics. J Clin Psychiatry 57(suppl. 11):12-25.
30. Fagiolini, A., Frank, E., Houck, P. R., et al. 2002. Prevalence of obesity and weight change during treatment in patients with bipolar I disorder. J Clin Psychiatry 63:528-533.
31. Ferrier, I. N., and Thompson, J. M. 2002. Cognitive impairment in bipolar affective disorder: implications for the bipolar diathesis. Br J Psychiatry 180:293-295.
32. Fliser, D., Franek, E., Joest, M., et al. 1997. Renal function in the elderly: impact of hypertension and cardiac function. Kidney Int 51:1196-1204.
33. Foster, J. R. 1992. Use of lithium in elderly psychiatry patients: a review of the literature. Lithium 3:77-93.
34. Fuller, M., and Sajatovic, M. 2002. Drug information handbook for psychiatry (3rd ed). Cleveland, OH: Lexi-Comp.
35. Glassman, A. H. 2005. Treatment of patients with bipolar disorder and cardiovascular disease. Curr Psychiatry 4(suppl.):21-33.
36. Himmelhoch, J. M., Neil, J. F., May, S. J., et al. 1980. Age, dementia, dyskinesias, and lithium response. Am J Psychiatry 137:941-945.
37. Johnston, A. M., and Eagles, J. M. 1999. Lithium-associated clinical hypothyroidism: prevalence and risk factors. Br J Psychiatry 175:336-339.
38. Juurlink, D. N., Herrmann, N., Szalai, J. P., et al. 2004. Medical illness and the risk of suicide in the elderly. Arch Intern Med 164:1179-1184.
39. Kasarskis, E. J., Kuo, C. S., Berger, R., et al. 1992. Carbamazepine-induced cardiac dysfunction: characterization of two distinct clinical syndromes. Arch Intern Med 152:186-191.
40. Kato, M. M., and Goodnick, P. J. 2001. Antipsychotic medication: effects on regulation of glucose and lipids. Expert Opin Pharmacother 2:1571-1582.
41. Kawa, I., Carter, J. D., Joyce, P. R., et al. 2005. Gender differences in bipolar disorder: age of onset, course, comorbidity, and symptom presentation. Bipolar Disord 7:119-125.
42. Keck, P. E., Buse, J. B., Dagogo-Jack, S., et al. 2003. Managing metabolic concerns in patients with severe mental illness. Postgraduate medicine special report. Minneapolis: Healthcare Information Programs, McGraw-Hill Healthcare Informations Group.
43. Kessing, L. V., and Andersen, P. K. 2004. Does the risk of developing dementia increase with the number of episodes in patients with depressive disorder and in patients with bipolar disorder? J Neurol Neurosurg Psychiatry 75:1662-1666.
44. Kessing, L. V., and Nilsson, F. M. 2003. Increased risk of developing dementia in patients with major affective disorders compared to patients with other medical illnesses. J Affect Disord 73:261-269.
45. Kilbourne, A. M., Cornelius, J. R., Han, X., et al. 2004. Burden of general medical conditions among individuals with bipolar disorder. Bipolar Disord 6:368-373.
46. Kilbourne, A. M., Cornelius, J. R., Han, X., et al. 2005. General-medical conditions in older patients with serious mental illness. Am J Geriatr Psychiatry 13:250-254.
47. Kleiner, J., Altshuler, L., Hendrick, V., et al. 1999. Lithium-induced subclinical hypothyroidism: review of the literature and guidelines for treatment. J Clin Psychiatry 60:249-255.
48. Krishnan, K. R. 2005. Psychiatric and medical comorbidities of bipolar disorder. Psychosom Med 67:1-8.
49. Kupka, R. W., Breunis, M. N., Knijff, E., et al. 2002a. Immune activation, steroid resistancy and bipolar disorder. Bipolar Disord 4(suppl.):73-74.
50. Kupka R. W., Nolen, W. A., Post, R. M., et al. 2002b. High rate of autoimmune thyroiditis in bipolar disorder: lack of association with lithium exposure. Biol Psychiatry 51:305-311.
51. Laurberg, P., Andersen, S., Bulow P. I., et al. 2005. Hypothyroidism in the elderly: pathophysiology, diagnosis, and treatment. Drugs Aging 22:23-38.
52. Lazarus, J. H. 1998. The effects of lithium therapy on thyroid and thyrotropin-releasing hormone. Thyroid 8:909-913.
53. Leipzig, R. M. 1990. Psychopharmacology in patients with hepatic and gastrointestinal disease. Int J Psychiatry Med 20:109-139.
54. Lindenmayer, J. P., Czobor, P., Volavka, J., et al. 2003. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. Am J Psychiatry 160:290-296.
55. Lustman, P. J., Anderson, R. J., Freedland, K. E., et al. 2000. Depression and poor glycemic control: a meta-analytic review of the literature. Diabetes Care 23:934-942.
56. Lyketsos, C. G., Corazzinini, K., and Steele, C. 1995. Mania in Alzheimer's disease. J Neurol Clin Neurosci 7:350-352.
57. Malhotra, S., and McElroy, S. L. 2002. Medical management of obesity associated with mental disorders. J Clin Psychiatry 63(suppl. 4):24-32.
58. Markowitz, G. S., Radhakrishnan, J., Kambham, N., et al. 2000. Lithium nephrotoxicity: a progressive combined glomerular and tubulointerstitial nephropathy. J Am Soc Nephrol 11:1439-1448.
59. Martinez-Aran, A., Vieta, E., Colom, F., et al. 2004. Cognitive impairment in euthymic bipolar patients: implications for clinical and functional outcome. Bipolar Disord 6:224-232.
60. Martire, L. M., Schulz, R., Mulsant, B. H., et al. 2004 Family caregiver functioning in late-life bipolar disorder. Am J Geriatr Psychiatry 12:335-336.
61. McElroy, S. L., Frye, M. A., Suppes, T., et al. 2002. Correlates of overweight and obesity in 644 patients with bipolar disorder. J Clin Psychiatry 63:207-213.
62. McIntyre, R. S., and Konarski, J. Z. 2005. Bipolar disorder, overweight/obesity, and disorders of glucose metabolism. Curr Psychiatry 4(suppl.):11-20.
63. McIntyre, R. S., McCann, S. M., and Kennedy, S. H., 2001. Antipsychotic metabolic effects: weight gain, diabetes mellitus, and lipid abnormalities. Can J Psychiatry 46:273-281.
64. McLaren, K. D., and Marangell, L. B. 2004. Special considerations in the treatment of patients with bipolar disorder and medical comorbidities. Ann Gen Hosp Psychiatry 3:7.
65. Panjehshahin, M. R., Bowman, C. J., and Yates, M. S. 1991. Effect of valproic acid, its unsaturated metabolites and some structurally related fatty acids on the binding of warfarin and dansylsacrosine to human albumin. Biochem Pharmacol 41:1227-1233.
66. Physicians' Desk Reference. 2005a. Geodon for injection. Physicians' desk reference (59th ed.) Montvale, NJ: Thomson.
67. Physicians' Desk Reference. 2005b. Risperidone. Physicians' desk reference (59th ed.) Montvale, NJ: Thomson.
68. Poirier, P., and Despres, J. P. 2003. Waist circumference, visceral obesity, and cardiovascular risk. J Cardiopulm Rehabil 23:161-169.
69. Pomara, N., Tun, H., Da Silva, D., et al. 1998. The acute and chronic performance effects of alprazolam and lorazepam in the elderly: relationship to duration of treatment and selfrated sedation. Psychopharmacol Bull 34:139-153.
70. Regenold, W. T., Thapar, R. K., Maran, C., et al. 2002. Increased prevalence of type 2 diabetes mellitus among psychiatric inpatients with bipolar I affective and schizoaffective disorders independent of psychotropic drug use. J Affect Disord 70:19-26.
71. Reiss, R. A., Haas, C. E, Karki, S. D., et al. 1994. Lithium pharmacokinetics in the obese. Clin Pharmacol Ther 55:392-398.
72. Richens, A. 1993. Clinical pharmacokinetics of gabapentin. In Chadwick, D. (ed.), New trends in epilepsy management: the role of gabapentin (pp. 41-46). London: Royal Society of Medicine.
73. Ruzickova, M., Slaney, C., Garnham, J., et al. 2003. Clinical features of bipolar disorder with and without comorbid diabetes. Can J Psychiatry 48:458-461.
74. Sajatovic, M., Madhusoodanan, S., and Coconcea, N. 2005. Managing bipolar disorder in the elderly: defining the role of the newer agents. Drugs Aging 22:39-54.
75. Sharma, R., and Markar, H. R. 1994. Mortality in affective disorder. J Affect Disord 31:91-96.
76. Shulman, K. I., Sykora, K., Gill, S. S., et al. 2005. New thyroxine treatment in older adults beginning lithium therapy. Am J Geriatr Psychiatry 13:299-304.
77. Smith, D. A., and Perry, P. J. 1992. Nonneuroleptic treatment of disruptive behavior in organic mental syndromes. Ann Pharmacother 26:1400-1408.
78. Snoeck, E., Van Peer, A., Sack, M., et al. 1995. Influence of age, renal and liver impairment on the pharmacokinetics of risperidone in man. Psychopharmacology 122:223-229.
79. Sowell, M. O., Mukhopadhyay, N., Cavazzoni, P., et al. 2002. Hyperglycemic clamp assessment of insulin secretory responses in normal subjects treated with olanzapine, risperidone, or placebo. J Clin Endocrinol Metab 87:2918-2923.
80. Spina, E., Scordo, M. G., and D'Arrigo, C. 2003. Metabolic drug interactions with new psychotropic agents. Fundam Clin Pharmacol 17:517-538.
81. Sproule, B. A., Hardy, B. G., and Shulman, K. I. 2000. Differential pharmacokinetics of lithium in elderly patients. Drugs Aging 16:165-177.
82. Steffens, D. C., and Krishnan, K. R. 1998. Structural neuroimaging and mood disorders: recent findings, implications for classification, and future directions. Biol Psychiatry 43:705-712.
83. Stoudemire, A., Hill, C. D., Lewison, B. J., et al. 1998. Lithium intolerance in a medicalpsychiatric population. Gen Hosp Psychiatry 20:85-90.
84. Swann, A. C. 2001. Major system toxicities and side effects of anticonvulsants. J Clin Psychiatry 62(suppl. 14):16-21.
85. Tariot, P. N., Schneider, L. S., Mintzer, J. E., et al. 2001. Safety and tolerability of divalproex sodium in the treatment of signs and symptoms of mania in elderly patients with dementia: results of a double-blind, placebo-controlled trial. Curr Ther Res 62:51-67.
86. Timmer, R. T., and Sands, J. M. 1999. Lithium intoxication. J Am Soc Nephrol 10:666-674.
87. Toalson, P., Ahmed, S., Hardy, T., et al. 2004. The metabolic syndrome in patients with severe mental illnesses. Prim Care Companion J Clin Psychiatry 6:152-158.
88. U. S. Food and Drug Administration. 2005. Public health advisory: deaths with antipsychotics in elderly patients with behavioral disturbances. April 11. www.fda.gov/cder/drug/advisory/antipsychotics.htm
89. Vanina, Y., Podolskaya, A., Sedky, K., et al. 2002. Body weight changes associated with psychopharmacology. Psychiatr Serv 53:842-847.
90. Wang, P. S., Schneeweiss, S., Avorn, J., et al. 2005. Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Engl J Med 353:2335-2241.
91. Watson, S., Gallagher, P., Ritchie, J. C., et al. 2004. Hypothalamic-pituitary-adrenal axis function in patients with bipolar disorder. Br J Psychiatry 184:496-502.
92. Wong, S. L., Cavanaugh, J., Shi, H., et al. 1996. Effects of divalproex sodium on amitriptyline and nortriptyline pharmacokinetics. Clin Pharmacol Ther 60:48-53.
93. Wylie, M. E., Mulsant, B. H., Pollock, B. G., et al. 1999. Age at onset in geriatric bipolar disorder: effects on clinical presentation and treatment outcomes in an inpatient sample. Am J Geriatr Psychiatry 7:77-83.
94. Young, R. C., Murphy, C. F., and De Asis, J. M. 2001. Executive dysfunction and treatment outcome in geriatric mania. Presented at Annual Meeting, American Psychiatric Association, New Research.
95. Young, R. C., Gyulai, L., Mulsant, B. H., et al. 2004. Pharmacotherapy of bipolar disorder in old age: review and recommendations. Am J Geriatr Psychiatry 12:342-357.